These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

709 related articles for article (PubMed ID: 15770489)

  • 1. Incidence of chemotherapy-induced nausea and vomiting in Taiwan: physicians' and nurses' estimation vs. patients' reported outcomes.
    Liau CT; Chu NM; Liu HE; Deuson R; Lien J; Chen JS
    Support Care Cancer; 2005 May; 13(5):277-86. PubMed ID: 15770489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics.
    Grunberg SM; Deuson RR; Mavros P; Geling O; Hansen M; Cruciani G; Daniele B; De Pouvourville G; Rubenstein EB; Daugaard G
    Cancer; 2004 May; 100(10):2261-8. PubMed ID: 15139073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perception of healthcare providers versus patient reported incidence of chemotherapy-induced nausea and vomiting after the addition of NK-1 receptor antagonists.
    Majem M; Moreno ME; Calvo N; Feliu A; Pérez J; Mangues MA; Barnadas A
    Support Care Cancer; 2011 Dec; 19(12):1983-90. PubMed ID: 21086141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment.
    Bloechl-Daum B; Deuson RR; Mavros P; Hansen M; Herrstedt J
    J Clin Oncol; 2006 Sep; 24(27):4472-8. PubMed ID: 16983116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan.
    Tamura K; Aiba K; Saeki T; Nakanishi Y; Kamura T; Baba H; Yoshida K; Yamamoto N; Kitagawa Y; Maehara Y; Shimokawa M; Hirata K; Kitajima M;
    Int J Clin Oncol; 2015 Oct; 20(5):855-65. PubMed ID: 25681876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy-induced nausea and vomiting is less controlled at delayed phase in patients with esophageal cancer: a prospective registration study by the CINV Study Group of Japan.
    Baba Y; Baba H; Yamamoto S; Shimada H; Shibata T; Miyazaki T; Yoshikawa T; Nakajima Y; Tsuji Y; Shimokawa M; Kitagawa Y; Aiba K
    Dis Esophagus; 2017 Feb; 30(2):1-7. PubMed ID: 27001532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of chemotherapy-induced nausea and vomiting in Mexico: healthcare provider predictions versus observed.
    Erazo Valle A; Wisniewski T; Figueroa Vadillo JI; Burke TA; Martinez Corona R
    Curr Med Res Opin; 2006 Dec; 22(12):2403-10. PubMed ID: 17257454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapy-induced nausea and vomiting in patients with breast cancer: a prospective cohort study.
    Naito Y; Kai Y; Ishikawa T; Fujita T; Uehara K; Doihara H; Tokunaga S; Shimokawa M; Ito Y; Saeki T
    Breast Cancer; 2020 Jan; 27(1):122-128. PubMed ID: 31407150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiemetic guideline consistency and incidence of chemotherapy-induced nausea and vomiting in US community oncology practice: INSPIRE Study.
    Gilmore JW; Peacock NW; Gu A; Szabo S; Rammage M; Sharpe J; Haislip ST; Perry T; Boozan TL; Meador K; Cao X; Burke TA
    J Oncol Pract; 2014 Jan; 10(1):68-74. PubMed ID: 24065402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baseline patient characteristics, incidence of CINV, and physician perception of CINV incidence following moderately and highly emetogenic chemotherapy in Asia Pacific countries.
    Hsieh RK; Chan A; Kim HK; Yu S; Kim JG; Lee MA; Dalén J; Jung H; Liu YP; Burke TA; Keefe DM
    Support Care Cancer; 2015 Jan; 23(1):263-72. PubMed ID: 25120009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study.
    Escobar Y; Cajaraville G; Virizuela JA; Álvarez R; Muñoz A; Olariaga O; Tamés MJ; Muros B; Lecumberri MJ; Feliu J; Martínez P; Adansa JC; Martínez MJ; López R; Blasco A; Gascón P; Calvo V; Luna P; Montalar J; Del Barrio P; Tornamira MV
    Support Care Cancer; 2015 Sep; 23(9):2833-40. PubMed ID: 26081597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Breakthrough chemotherapy-induced nausea and vomiting: report of a nationwide survey by the CINV Study Group of Japan.
    Tamura K; Aiba K; Saeki T; Nakanishi Y; Kamura T; Baba H; Yoshida K; Yamamoto N; Kitagawa Y; Maehara Y; Shimokawa M; Hirata K; Kitajima M;
    Int J Clin Oncol; 2017 Apr; 22(2):405-412. PubMed ID: 27909835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy-induced nausea and vomiting (CINV) in 190 colorectal cancer patients: a prospective registration study by the CINV study group of Japan.
    Tsuji Y; Baba H; Takeda K; Kobayashi M; Oki E; Gotoh M; Yoshida K; Shimokawa M; Kakeji Y; Aiba K
    Expert Opin Pharmacother; 2017 Jun; 18(8):753-758. PubMed ID: 28395603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study.
    Hilarius DL; Kloeg PH; van der Wall E; van den Heuvel JJ; Gundy CM; Aaronson NK
    Support Care Cancer; 2012 Jan; 20(1):107-17. PubMed ID: 21258948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy.
    Rapoport B; Schwartzberg L; Chasen M; Powers D; Arora S; Navari R; Schnadig I
    Eur J Cancer; 2016 Apr; 57():23-30. PubMed ID: 26851398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of neurokinin-1 receptor antagonists in patients receiving moderately or highly emetogenic chemotherapy.
    Rogers MP; Blackburn L
    Clin J Oncol Nurs; 2010 Aug; 14(4):500-4. PubMed ID: 20682506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective observational study on chemotherapy-induced nausea and vomiting (CINV) in patients with gynecologic cancer by the CINV Study Group of Japan.
    Mizuno M; Hiura M; Kikkawa F; Numa F; Yaegashi N; Narahara H; Aoki D; Kimura E; Kato H; Shimokawa M; Sugiyama T; Kamura T
    Gynecol Oncol; 2016 Mar; 140(3):559-64. PubMed ID: 26748216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly emetogenic chemotherapy: results of a prospective, randomized, double-blind, noninferiority phase 3 trial.
    Raftopoulos H; Cooper W; O'Boyle E; Gabrail N; Boccia R; Gralla RJ
    Support Care Cancer; 2015 Mar; 23(3):723-32. PubMed ID: 25179689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiemetic therapy in Asia Pacific countries for patients receiving moderately and highly emetogenic chemotherapy--a descriptive analysis of practice patterns, antiemetic quality of care, and use of antiemetic guidelines.
    Yu S; Burke TA; Chan A; Kim HK; Hsieh RK; Hu X; Liang JT; Baños A; Spiteri C; Keefe DM
    Support Care Cancer; 2015 Jan; 23(1):273-82. PubMed ID: 25115892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A retrospective study on chemotherapy-induced nausea and vomiting in highly/moderately emetogenic chemotherapy: incidence and prescribing practice.
    Badarudin NS; Mohamed Shah N; Mohd Kassim KNB; Ismail F; Islahudin F; Mohd Tahir NA; Yusak S
    Support Care Cancer; 2022 Jun; 30(6):5339-5349. PubMed ID: 35290510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.